Biofrontera AG operates as a biopharmaceutical enterprise, dedicated to the exploration, evolution, and commercialization of dermatological therapies. Its flagship offerings, Ameluz and the BF-RhodoLED lamp, are utilized for treating mild to moderate actinic keratoses on the face and scalp, managing field cancerization, and addressing life-threatening squamous cell carcinoma. The company is also advancing RhodoLED XL, intended for extensive interspersed lesions, and provides Belixos, an innovative cosmetic product designed for sensitive and irritated skin.